Abstract 2268
Background
Ring-type dedicated breast positron emission tomography (DbPET) can detect small breast cancers; however, there are no category classifications of abnormal findings on DbPET such as BI-RADs (mammography, ultrasonography, and magnetic resonance imaging). We investigated whether the classification of DbPET findings was useful for detecting breast cancer.
Methods
A total of 674 patients with breast cancers underwent ring-type DbPET using FDG before treatment between January 2016 and March 2019. Findings were morphologically categorized as a focus (uptake size ≤5 mm), mass (>6 mm), or non-mass (multiple uptakes). Non-mass uptakes were additionally classified based on the distribution: focal, linear, regional, segmental, and diffuse. Maximum standardized uptake value (SUVmax) and tumor-to-normal tissue ratio (TNR) were calculated. The final diagnosis was pathologically evaluated based on biopsy or surgical specimens, and lesions of category 2 or lower by conventional examinations were determined benign.
Results
Among 867 abnormal findings, 668 (77%) were malignant and 199 (23%) were benign. Morphologically, 187 (21.6%) lesions were foci, 413 (47.6%) were masses, and 267 (30.8%) were non-masses. Among non-mass lesions, 131 focal, 1 linear, 15 regional, 115 segmental, and 5 diffuse distributions were presented. The median SUVmax was 5.0 and TNR was 2.8. The area under the curve values of SUVmax and TNR for predicting malignancy were 0.824 and 0.855, respectively. In a multivariate analysis, mass, focal and segmental distributions of non-mass lesions, high TNR were significantly related with breast cancer (all P < 0.001). Pathologically confirmed benign lesions included 45 mastopathies, 29 papillomas, 10 fibroadenomas, 7 ductal adenomas, and 3 others.
Conclusions
Classification using morphological findings and TNRs on DbPET are useful to detect breast cancer. The DbPET classification should be considered for breast cancer screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract